Artiva Biotherapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ARTV Nasdaq 2830 www.artivabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026 - Oct 2nd, 2026 7:05 am
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026) - Oct 1st, 2026 5:30 am
Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease - Sep 23rd, 2026 5:30 am
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum - Sep 17th, 2026 6:00 am
Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026 - Sep 8th, 2026 5:30 am
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September - Sep 2nd, 2026 6:30 am
Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Aug 6th, 2026 2:05 pm
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jul 17th, 2026 5:30 am
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year? - Jul 8th, 2026 7:40 am
Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - Jun 23rd, 2026 2:05 pm
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today - Jun 8th, 2026 4:30 am
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - May 28th, 2026 6:00 am
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases - May 19th, 2026 2:05 pm
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development - May 19th, 2026 6:00 am
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - May 8th, 2026 4:52 am
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights - May 8th, 2026 4:31 am
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026 - May 8th, 2026 4:30 am
Is Artiva Biotherapeutics (NASDAQ:ARTV) In A Good Position To Deliver On Growth Plans? - Apr 17th, 2026 12:15 pm
Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham - Apr 15th, 2026 4:02 pm
Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference - Apr 8th, 2026 6:00 am